
Edyta Maria Urbanska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4587661/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2022, , .	1.5	7
2	Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. Clinical Lung Cancer, 2021, 22, e528-e532.	1.1	8
3	Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer. Clinics and Practice, 2021, 11, 293-302.	0.6	3
4	P46.03 Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, S1094.	0.5	1
5	P10.06 Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC. Journal of Thoracic Oncology, 2021, 16, S1000-S1001.	0.5	0
6	P46.02 Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib. Journal of Thoracic Oncology, 2021, 16, S1093-S1094.	0.5	1
7	Treatment Algorithm for Advanced ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, e156-e157.	0.5	2
8	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences, 2020, 21, 2847.	1.8	25
9	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 2019, 11, 923.	1.7	124
10	P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT. Journal of Thoracic Oncology, 2018, 13, S946.	0.5	1
11	Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. Lung Cancer, 2017, 113, 14-17.	0.9	20
12	P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations. Journal of Thoracic Oncology, 2017, 12, S2203.	0.5	0
13	Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat) Tj ETQq1 adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Research Notes, 2013, 6, 489.	1 0.784314 0.6	rgBT /Overld 39